Clinical Trial Update: Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants [Phase 1]

View source ↗

Summary

Phase 1 trial comparing DehydraTECH-CBD and DehydraTECH-GLP1 agonists, alone or in combination, in overweight/obese participants including those with prediabete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Prediabetes
• Type 2 Diabetes Mellitus

Drugs mentioned

• DehydraTECH-CBD (cannabidiol with DehydraTECH technology)
• DehydraTECH-CBD + DehydraTECH-GLP1 agonist (cannabidiol + GLP-1 receptor agonist)
• DehydraTECH-GLP1 agonist (GLP-1 receptor agonist)

Snippet

Sponsor: Lexaria Bioscience Corp. | Conditions: Type2diabetes | Phase 1 | Status: COMPLETED